Posts Tagged ‘ AMD ’
Submacular hemorrhages may be managed with anti-VEGF
WAIKOLOA, Hawaii — Intravitreal injections may successfully help manage submacular hemorrhages, according to a speaker here.“We know that submacular hemorrhages have a significant variability in their clinical course,” Mark W. Johnson, MD, said at Retina 2013. “But it does seem that poor prognostic factors include thick blood under the fovea and the presence of AMD. And we know that when an eye has both of these factors, the final visual outcome if you don’t treat these is rarely better than 20/200.”
A safety review and meta-analyses of bevacizumab and ranibizumab in age related macular degeneration: Off-label versus gold standard
Source: PLoS One
Area: News
The authors of this paper carried out a systematic review based on randomised controlled clinical trials (RCTs) to assess whether unlicensed therapy with bevacizumab is as safe as licensed therapy with ranibizumab for the treatment of age related macular degeneration (AMD), and whether bevacizumab can be justifiably offered to patients with AMD as a medication with no additional risk. The authors also evaluated whether adverse effects (AEs) are dose-related. Data for the review were sourced from various databases (Embase, Medline, and Cochrane Library) and phase 3/4 RCTs with at least a follow up period of 1 year were included. The trials investigated bevacizumab or ranibizumab in direct comparison (head-to-head) or against any other control group (indirect comparison). The inclusion criteria were met by 11 RCTs. The following results are reported: Direct comparison (3 trials, 1333 patients): . The one year data show a ...
Area: News
The authors of this paper carried out a systematic review based on randomised controlled clinical trials (RCTs) to assess whether unlicensed therapy with bevacizumab is as safe as licensed therapy with ranibizumab for the treatment of age related macular degeneration (AMD), and whether bevacizumab can be justifiably offered to patients with AMD as a medication with no additional risk. The authors also evaluated whether adverse effects (AEs) are dose-related. Data for the review were sourced from various databases (Embase, Medline, and Cochrane Library) and phase 3/4 RCTs with at least a follow up period of 1 year were included. The trials investigated bevacizumab or ranibizumab in direct comparison (head-to-head) or against any other control group (indirect comparison). The inclusion criteria were met by 11 RCTs. The following results are reported: Direct comparison (3 trials, 1333 patients): . The one year data show a ...
Potential Major Breakthrough in Treatment of Wet Age-Related Macular Degeneration
A single injection of a new gene therapy treatment from Avalanche Biotech could possibly stop the advance of neovascularization in the wet form of AMD for several years. Human clinical trials are currently underway.
Here is how I commented about this breakthrough in my writeup:...
A Novel Gene Therapy Approach to Treating the Wet Form of AMD: The BioFactoryTM From Avalanche Biotech
I originally contacted this company in November 2010, when they were still in “stealth mode” and weren't able to share details about what they were doing. Recently, the company got back in touch to provide an update, having announced, in December 2011, a clinical trial of their gene therapy approach to treating the wet form of AMD.
Extend-and-Treat Bevacizumab Regimen Ups Vision in Wet AMD
Patients with wet age-related macular degeneration who received bevacizumab on an extend-and-treat regimen had significantly improved vision, as well as fewer office visits, tests, and injections.
Medscape Medical News
Medscape Medical News
Genes That Enable Diagnosis Of Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide, especially in developed countries, and there is currently no known treatment or cure or for the vast majority of AMD patients...
Eylea Has Already Begun to Be Used by U.S. Retinal Specialists One Month Post-Launch, According to a Recent BioTrends Report
The LaunchTrends: Eylea Wave 1 report, which measures product uptake and commercial effectiveness at one month post launch, finds that 40% of surveyed retinal specialists have initiated trial on Regenerons Eylea, the newest treatment for wet age-related macular degeneration (wet AMD). One key advantage of Eylea over its main competitors, Genentechs Lucentis and Avastin, is the formal dosing schedule, which allows dosing every eight weeks following an initial three monthly doses...
Further data for aflibercept in neovascular age-related macular degeneration
Source: BioSpace
Area: News
BioSpace has reported on the results of an integrated analysis of two Phase III studies (VIEW 1 and VIEW 2) of aflibercept intravitreal injection in the treatment of neovascular age-related macular degeneration (wet AMD). The 52-week results from the studies have previously been reported; the current data are from a further analysis at 96 weeks.
Area: News
BioSpace has reported on the results of an integrated analysis of two Phase III studies (VIEW 1 and VIEW 2) of aflibercept intravitreal injection in the treatment of neovascular age-related macular degeneration (wet AMD). The 52-week results from the studies have previously been reported; the current data are from a further analysis at 96 weeks.
Does the Implantable Telescope Materially Improve the Quality of Life of AMD Sufferers?
In a past post we had reported on a new treatment for end-stage age-related macular degeneration (AMD): an implantable miniature telescope (IMT) that amplifies vision and was approved by the FDA in Summer 2010.
But does this device provide enough of an improvement in quality of life to be worth the trouble and cost?
NETAG supports use of intravitreal bevacizumab for the management of age-related macular degeneration
Source: NETAG
Area: Evidence > Drug Specific Reviews
The North East Treatment Advisory Group (NETAG) has produced an updated appraisal of bevacizumab for the management of neovascular age-related macular degeneration and recommended bevacizumab 1.25 mg intravitreal injection as cost effective treatment option for this condition. The group was satisfied that the relative clinical efficacy and safety of bevacizumab for AMD had been adequately demonstrated. It should be noted that bevacizumab is not licensed for any ophthalmic indication. Ranibizumab is licensed for wet age-related macular degeneration and there is NICE guidance available which supports ranibizumab in this indication. The Group was concerned about the implications of using an unlicensed treatment where a licensed alternative treatment is currently used, and was mindful of concerns raised by clinicians regarding prescribing responsibilities and patient information. However, it was felt that these issues were not impossible to address and could be ...
Area: Evidence > Drug Specific Reviews
The North East Treatment Advisory Group (NETAG) has produced an updated appraisal of bevacizumab for the management of neovascular age-related macular degeneration and recommended bevacizumab 1.25 mg intravitreal injection as cost effective treatment option for this condition. The group was satisfied that the relative clinical efficacy and safety of bevacizumab for AMD had been adequately demonstrated. It should be noted that bevacizumab is not licensed for any ophthalmic indication. Ranibizumab is licensed for wet age-related macular degeneration and there is NICE guidance available which supports ranibizumab in this indication. The Group was concerned about the implications of using an unlicensed treatment where a licensed alternative treatment is currently used, and was mindful of concerns raised by clinicians regarding prescribing responsibilities and patient information. However, it was felt that these issues were not impossible to address and could be ...
Stem Cells in Ophthalmology Update 9: First Patients Treated
As I reported back on June 16th, Advanced Cell Technology had enrolled the first two patients in its Phase I/II clinical trials using retinal pigment epithelial (RPE) cells derived from embryonic stem cells (hESCs) for treating Stargardt’s Macular Dystrophy (SMD) and for the treatment of the dry form of age-related macular degeneration (Dry AMD). The company announced today that these first patients had now successfully received their first dose of the stem cells.
New Human Embryonic Stem Cell Study For Dry AMD And Stargardt’s Macular Dystrophy
Two patients have been treated using RPE (retinal pigment epithelial) cells derived from hESCs (human embryonic stem cells) in two Phase 1/2 clinical trials for dry age-related macular degeneration and Stargardt's macular dystrophy, Advanced Cell Technology Inc. has announced.
Avastin Just as Good as Lucentis
It's official. Avastin is just as good as Lucentis for the treatment of wet macular degeneration.
The results of this National Eye Institute study were released just a week ago. The study, Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) compared the two drugs head-to-head in a year long study involving about 1200 patients.
Better still, the study showed that dosing “as needed” may be just as good a therapy a (Read more...)
CATT Update 15: Preliminary Two-Year Safety Data Presented at ARVO
Two of the authors of the CATT Study, that was published in the NEJM last Thursday, Drs. Dan Martin and Maureen McGovern, presented additional information about the study at the opening day ARVO Meeting, to about 2000 eager attendees. As reported by MedPageToday, their presentation included preliminary two-year safety data from the landmark CATT trial.
Neurotech’s NT-501 Implant Slows Vision Loss in Patients with Geographic Atrophy Associated with Dry AMD as Reported in PNAS
LINCOLN, R.I.--(BUSINESS WIRE)--Neurotech announced that it was reported in PNAS that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy associated with dry AMD in a Phase 2 study.
ASA: Strokes, Eye Disorder May Go Hand in Hand (CME/CE)
LOS ANGELES (MedPage Today) -- Hemorrhagic stroke appears more likely with advanced age-related macular degeneration (AMD), perhaps because of common underlying risk factors, a population-based study showed.
Advanced macular degeneration is associated with an increased risk of bleeding stroke, study finds
In the first study to examine stroke subtypes in age-related macular degeneration (AMD), older people with late-stage AMD appear to be at increased risk of bleeding stroke, but not a stroke caused by a blood clot in the brain. However the findings are preliminary and earlier stage AMD was not linked with any type of stroke.
New Therapies for “Dry” Macular Degeneration Under Development Based on Enzyme and DNA Research
New research has elucidated that low levels of the DICER-1 enzyme causes the buildup of toxic Alu DNA, or “junk DNA,” which causes the retinal cell death seen in “dry” macular degeneration. Through this new understanding, novel therapies can be developed that aim to prevent the build-up of Alu DNA.
NeoVista Epi-Retinal Strontium 90 Treatment for AMD: Update 4
NeoVista just released an update, discussing the first commercial utilization of its Epimacular Brachytherapy device in Germany. The Epi-Rad device, now renamed as the VIDION ANV (Anti Neo Vascular Therapy System) has been commercialized in Europe since November 2009. The first patients treated were in Pisa, Italy, quickly followed by patients treated in London, UK, also in November of 2009, and now in Hamburg, Germany this month.
Macular Degeneration Declining in the U.S.
The prevalence of macular degeneration may be decreasing in the United States! A study just released indicates that the rate of this blinding eye disease has decreased by about 15-20% compared to 20 years ago.
Subscribe
